Biopharma dealmaking in 2025.
(2026) 2025 FDA approvals: volume maintained, but value remains below average.
(2026) 2025 FDA approvals.
(2026) Hunting for biopharma's innovation sweet spot.
(2026) Strategies for blood-brain barrier rejuvenation and repair.
(2026) Roads and detours for CAR T cell therapy in autoimmune diseases.
(2026) Olfactory receptor activation overcomes obesity.
(2026) The Biomarkers Consortium: 20 years of advancing precision medicine.
(2026) First antibody-mimetic adnectin nabs an FDA approval.
(2026) Lilly pays US$1.2 billion for Ventyx and its oral anti-inflammatories.
(2026) Redirecting mast cells for antigen-specific cancer immunotherapy.
(2026) Kinase inhibitors trigger target degradation.
(2026) Histone methyltransferase inhibition hampers prostate cancer.
(2026) Boosting CAR T cell efficacy.
(2026) Nonopioid analgesic alleviates neuropathic pain.
(2026) Innate immune receptor agonist for cancer immunotherapy.
(2026) Prime editing to suppress nonsense mutations.
(2026) Promoting prostaglandin signalling for joint repair in osteoarthritis.
(2026) Novel drug treatments for schizophrenia.
(2026) Pharmacological targeting of the JAK–STAT pathway: new concepts and emerging indications.
(2026) Targeting extrachromosomal DNA in human cancers.
(2026) Therapeutic targeting of neuroimmune mechanisms in neurodegeneration.
(2026) FDA approves 100th small-molecule kinase inhibitor.
vol.24 iss.12 (2025) "It's about time": T regs win the Nobel prize.
vol.24 iss.12 (2025) Cancer cachexia contender enters first pivotal trial.
vol.24 iss.11 (2025) FDA approves BTK inhibitor for chronic hives.
vol.24 iss.11 (2025) Roche buys MASH contender for up to US$3.5 billion.
vol.24 iss.11 (2025) FDA new drug approvals in Q3 2025.
vol.24 iss.11 (2025) Innovation in medicines for global health: a 20-year landscape analysis.
vol.24 iss.11 (2025) Embracing the avoid-ome.
vol.24 iss.11 (2025) Designer peptide retunes channel function.
vol.24 iss.11 (2025) Macrocyclic peptides challenge cell cycle defects.
vol.24 iss.11 (2025) Epigenetic inhibitor silences KRAS-driven oncogenes.
vol.24 iss.10 (2025) Gut microbiota-derived metabolite drives atherosclerosis.
vol.24 iss.10 (2025) FDA approves first factor XIIa inhibitor, for hereditary angioedema.
vol.24 iss.8 (2025) A neonatal window for in vivo gene therapy in haematopoietic stem cells.
vol.24 iss.8 (2025) Stealthy polymer attacks Gram-negative bacteria.
vol.24 iss.8 (2025) In utero ASO therapy for spinal muscular atrophy.
vol.24 iss.7 (2025) FDA approves l-amino acid decarboxylase deficiency gene therapy
vol.24 iss.1 (2025) pp.1 Upcoming FDA approval decisions in Q1 2025
vol.24 iss.1 (2025) pp.1 Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery.
(2025) 2024 FDA approvals.
(2025) Engineered T cells traverse new terrain.
(2025) Lipid nanoparticle ferries therapeutic mRNA to the placenta.
(2025) DNA-PKcs inhibitor causes genomic alterations.
(2025) Human brain organoids identify glioma inhibitors.
(2025) Sodium channel blocker reduces skin inflammation.
(2025) Cough suppressant reverses lung scarring.
(2025) Base editing reduces prion protein.
(2025) J&J buys Intra-Cellular Therapies for US$14.6 billion, expanding its neuroscience portfolio.
(2025)
(2026) 2025 FDA approvals: volume maintained, but value remains below average.
(2026) 2025 FDA approvals.
(2026) Hunting for biopharma's innovation sweet spot.
(2026) Strategies for blood-brain barrier rejuvenation and repair.
(2026) Roads and detours for CAR T cell therapy in autoimmune diseases.
(2026) Olfactory receptor activation overcomes obesity.
(2026) The Biomarkers Consortium: 20 years of advancing precision medicine.
(2026) First antibody-mimetic adnectin nabs an FDA approval.
(2026) Lilly pays US$1.2 billion for Ventyx and its oral anti-inflammatories.
(2026) Redirecting mast cells for antigen-specific cancer immunotherapy.
(2026) Kinase inhibitors trigger target degradation.
(2026) Histone methyltransferase inhibition hampers prostate cancer.
(2026) Boosting CAR T cell efficacy.
(2026) Nonopioid analgesic alleviates neuropathic pain.
(2026) Innate immune receptor agonist for cancer immunotherapy.
(2026) Prime editing to suppress nonsense mutations.
(2026) Promoting prostaglandin signalling for joint repair in osteoarthritis.
(2026) Novel drug treatments for schizophrenia.
(2026) Pharmacological targeting of the JAK–STAT pathway: new concepts and emerging indications.
(2026) Targeting extrachromosomal DNA in human cancers.
(2026) Therapeutic targeting of neuroimmune mechanisms in neurodegeneration.
(2026) FDA approves 100th small-molecule kinase inhibitor.
vol.24 iss.12 (2025) "It's about time": T regs win the Nobel prize.
vol.24 iss.12 (2025) Cancer cachexia contender enters first pivotal trial.
vol.24 iss.11 (2025) FDA approves BTK inhibitor for chronic hives.
vol.24 iss.11 (2025) Roche buys MASH contender for up to US$3.5 billion.
vol.24 iss.11 (2025) FDA new drug approvals in Q3 2025.
vol.24 iss.11 (2025) Innovation in medicines for global health: a 20-year landscape analysis.
vol.24 iss.11 (2025) Embracing the avoid-ome.
vol.24 iss.11 (2025) Designer peptide retunes channel function.
vol.24 iss.11 (2025) Macrocyclic peptides challenge cell cycle defects.
vol.24 iss.11 (2025) Epigenetic inhibitor silences KRAS-driven oncogenes.
vol.24 iss.10 (2025) Gut microbiota-derived metabolite drives atherosclerosis.
vol.24 iss.10 (2025) FDA approves first factor XIIa inhibitor, for hereditary angioedema.
vol.24 iss.8 (2025) A neonatal window for in vivo gene therapy in haematopoietic stem cells.
vol.24 iss.8 (2025) Stealthy polymer attacks Gram-negative bacteria.
vol.24 iss.8 (2025) In utero ASO therapy for spinal muscular atrophy.
vol.24 iss.7 (2025) FDA approves l-amino acid decarboxylase deficiency gene therapy
vol.24 iss.1 (2025) pp.1 Upcoming FDA approval decisions in Q1 2025
vol.24 iss.1 (2025) pp.1 Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery.
(2025) 2024 FDA approvals.
(2025) Engineered T cells traverse new terrain.
(2025) Lipid nanoparticle ferries therapeutic mRNA to the placenta.
(2025) DNA-PKcs inhibitor causes genomic alterations.
(2025) Human brain organoids identify glioma inhibitors.
(2025) Sodium channel blocker reduces skin inflammation.
(2025) Cough suppressant reverses lung scarring.
(2025) Base editing reduces prion protein.
(2025) J&J buys Intra-Cellular Therapies for US$14.6 billion, expanding its neuroscience portfolio.
(2025)
